Morgan Stanley initiates Generate Biomedicines stock at overweight

try{ var _=i o; . if(!_||_&&typeof _==="object"&&_.expiry Traders placed $580M in oil bets minutes before Trump’s Iran post Trump delays strikes on Iranian power plants, says talks with Tehran "very good" Wall Street averages end more than 1% higher on Middle East de-escalation hopes Oil prices jump over 4% after Iran refutes US talks claims (South Africa Philippines Nigeria) Morgan Stanley initiates Generate Biomedicines stock at overweight By Analyst Ratings Published 03/24/2026, 04:33 AM Morgan Stanley initiates Generate Biomedicines stock at overweight 0 GENB 2.04% Investing.com - Morgan Stanley initiated coverage on Generate Biomedicines (NASDAQ:GENB) with an overweight stock rating and a price target of $20.00. The stock currently trades at $12.52, giving the company a market cap of $1.6 billion, though InvestingPro analysis suggests the shares are overvalued at current levels. The investment case centers on GB-0895, an AI-engineered, long-acting anti-TSLP monoclonal antibody in Phase 3 for severe asthma with a parallel development path in COPD. The firm also cited two emerging oncology programs, GB-4362 and GB-5267, as supporting assets that provide early validation of the company’s AI-first discovery platform. GB-0895 combines femtomolar affinity of approximately 106 fM with an extended terminal half-life of roughly 98 days, enabling subcutaneous dosing once every 26 weeks versus the current market leader Tezspire’s monthly regimen. Tezspire recorded 2025 global sales of approximately $1.9 billion. In Phase 1, GB-0895 showed sustained six-month suppression of asthma-relevant biomarkers, including eosinophils, FeNO, IL-5, and IL-13, with a clean safety profile. The dosing schedule supports a potentially meaningful adherence advantage in a market where only approximately 20% of patients remain fully adherent to current biologics.Like many early-stage biotech firms, Generate remains unprofitable with a loss of $4.98 per share over the last twelve months, though...